In breast cancer, EZH2 is now an important marker of aggressive behavior, with strong evidence for transcriptional repression and neoplastic transformation in cell-line studies [15], and higher expression in metastatic lesions than in primary lesions [14]. Here, EZH2 is linked to breast cancer.